Is acid phosphatase (PAP) still justified in the management of prostatic cancer?
The usefulness of acid phosphatase (PAP) and prostate specific antigen (PSA) is compared. The author concludes that PSA is more sensitive, has better organ specificity, does less diurnal variations and correlates better with tumor which makes PSA superior for staging and monitoring of therapy in prostate cancer.